Omada Health, Inc. (OMDA)
| Market Cap | 1.46B +33.3% |
| Revenue (ttm) | 309.76M +47.6% |
| Net Income | 4.31M |
| EPS | 0.07 |
| Shares Out | 61.22M |
| PE Ratio | 325.28 |
| Forward PE | 48.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,552,408 |
| Open | 24.00 |
| Previous Close | 24.01 |
| Day's Range | 23.60 - 24.09 |
| 52-Week Range | 10.28 - 26.92 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 27.50 (+15.35%) |
| Earnings Date | Aug 6, 2026 |
About OMDA
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for emplo... [Read more]
Financial Performance
In 2025, Omada Health's revenue was $260.21 million, an increase of 53.24% compared to the previous year's $169.80 million. Losses were -$12.78 million, -72.89% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OMDA stock is "Buy." The 12-month stock price target is $27.5, which is an increase of 15.35% from the latest price.
News
Omada Health Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company has evolved from a single-product focus to a broad cardiometabolic suite, achieving record revenue and margin expansion through channel partnerships and operational efficiencies. Seasonality affects growth, but new partnerships and product launches, especially in GLP-1, are driving future opportunities.
Omada Health price target raised to $35 from $30 at BTIG
BTIG raised the firm’s price target on Omada Health (OMDA) to $35 from $30 and keeps a Buy rating on the shares after it’s better than expected results. The company…
Omada Health guidance ‘could raise questions,’ says Canaccord
Canaccord views Omada Health’s (OMDA) Q2 report as strong but says the company’s guidance “could raise questions.” The Q3 and Q4 revenue and adjusted EBITDA outlook implies a step-down from…
Omada Health price target raised to $24 from $18 at BMO Capital
BMO Capital raised the firm’s price target on Omada Health (OMDA) to $24 from $18 and keeps an Outperform rating on the shares. Omada Health delivered a strong Q2 beat…
Omada Health reports Q2 EPS 8c, consensus 6c
Reports Q2 revenue $88M, consensus $80.06M. Reports Q2 total members increased 45% year-over-year, reflecting continued demand across the company’s integrated cardiometabolic care platform. “Our outst...
Omada Health raises FY26 revenue guidance to $334M-$340M from $322M-$330M
Consensus $327.97M. Raises FY26 adjusted EBITDA view to $21M-$27M from $14M-$20M. “At the midpoint, our raised full-year outlook represents approximately 30% year-over-year revenue growth and a fourfo...
Omada Health Earnings Call Transcript: Q2 2026
Record Q2 results featured 43% revenue growth, 73% GAAP gross margin, and $5M net income, prompting raised full-year guidance. Diabetes and Hypertension programs led growth, while new offerings like cholesterol and GLP-1 prescribing expanded the addressable market.
Omada Health Earnings release: Q2 2026
Omada Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Omada Health Slides: Q2 2026
Omada Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Omada Health Quarterly report: Q2 2026
Omada Health has published its Q2 2026 quarterly earnings report on August 6, 2026.
Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition
Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Chie...
Omada Health price target raised to $25 from $20 at Barclays
Barclays analyst Saket Kalia raised the firm’s price target on Omada Health (OMDA) to $25 from $20 and keeps an Overweight rating on the shares. The firm expects the company…
UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2026 results on Thu...
Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on August 6, 2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2026 results on Thu...
Omada Health price target raised to $28 from $24 at Canaccord
Canaccord raised the firm’s price target on Omada Health (OMDA) to $28 from $24 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Omada Health price target raised to $27 from $21 at Citizens
Citizens raised the firm’s price target on Omada Health (OMDA) to $27 from $21 and keeps an Outperform rating on the shares. Heading into Q2 earnings, Omada Health remains a…
Omada Health initiated with a Buy at BTIG
BTIG initiated coverage of Omada Health (OMDA) with a Buy rating and $30 price target The firm believes the company is well positioned to benefit from the healthcare industry’s transformation…
Omada Health to Host its First Investor Day on September 10, 2026
SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will host its first Inves...
Omada Health app download growth decelerated in Q2, says Morgan Stanley
Morgan Stanley reports that Omada Health (OMDA) app downloads increased 21% year-over-year in Q2, slowing from 37% and 72% growth in the past two quarters, adding that moderating app downloads…
Omada Health to Participate in Canaccord Genuity's 46th Annual Growth Conference
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in Canac...
Omada Health has ‘catch up potential,’ says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach says it is “overlooked” that Omada Health (OMDA) is significantly more profitable at their current revenue than where Hinge Health (HNGE) was at similar revenue...
Omada Health Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, and auditor ratification. Both proposals passed, with preliminary results to be filed on Form 8-K. Quorum was achieved with 70% of shares represented.
Omada Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Surpassing IPO targets, the company achieved 43% Q1 revenue growth and record margins, driven by a durable, tech-enabled care model and expanding clinical offerings. Strategic PBM partnerships and rapid product innovation, especially in GLP-1 care, position it for continued growth.
Omada Health to Participate in Goldman Sachs Global Healthcare Conference
SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Go...
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and Big Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Napco Security Technologies ($NSSC), MP Materials ($MP), and Omada Health, Inc. ($OMDA) a...